

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM501364

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
The Bank of New York Mellon		12/07/2018	Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Bausch Health Companies Inc. (f.k.a. Valeant Pharmaceuticals International, Inc.)		
Street Address:	400 Somerset Corporate Blvd.		
City:	Bridgewater		
State/Country:	NEW JERSEY		
Postal Code:	08807		
Entity Type:	Corporation: BRITISH COLUMBIA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	3460627	TERMINATOR 10	
CORRESPONDENCE DATA			
Fax Number:	8004947512		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	202-370-4756		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	Jay daSilva		
Address Line 1:	1025 Vermont Ave NW, Suite 1130		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	Washington, D.C. 20005		
ATTORNEY DOCKET NUMBER:	1024283 TM REL - BONY		
NAME OF SUBMITTER:	Brandon H. Okun		
SIGNATURE:	/Brandon H. Okun/		
DATE SIGNED:	12/10/2018		
Total Attachments: 5			
source=#91550764v1 - (Valeant - L_Oreal - Terminator 10 TM Release (BONY))#page2.tif			
source=#91550764v1 - (Valeant - L_Oreal - Terminator 10 TM Release (BONY))#page3.tif			
source=#91550764v1 - (Valeant - L_Oreal - Terminator 10 TM Release (BONY))#page4.tif			

OP \$40.00 3460627

source=#91550764v1 - (Valeant - L_Oreal - Terminator 10 TM Release (BONY))#page5.tif

source=#91550764v1 - (Valeant - L_Oreal - Terminator 10 TM Release (BONY))#page6.tif

RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS

This RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS (this “Release”) is entered into as of December 7, 2018 by The Bank of New York Mellon, as Collateral Agent for the Noteholder Secured Parties (the “Assignor”), in favor of Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia, with offices located at 2150 St. Elzear Blvd. West, Laval, Quebec H7L 4A8,, (the “Assignee”). Capitalized terms used in this Release but not defined herein shall have the respective meanings ascribed to such terms in the Security Agreements or Trademark Security Agreements (each as defined below), as applicable.

WHEREAS, reference is made to (i) that certain U.S. Pledge and Security Agreement dated as of March 21, 2017 (as it may be amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “March Security Agreement”), between the other grantors party thereto, the Assignee and the Assignor; (ii) that certain U.S. Pledge and Security Agreement dated as of October 17, 2017, between the other grantors party thereto, the Assignee and the Assignor (as it may be amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “October Security Agreement” and together with the March Security Agreement, the “Security Agreements”); (iii) that certain Trademark Security Agreement, dated as of July 17, 2017 between the Assignor (as collateral agent), the Assignee and other grantors party thereto (the “March Bond TMSA”); and (iv) that certain Trademark Security Agreement, dated as of February 13, 2018 between the Assignor (as collateral agent) and the Assignee and other grantors party thereto (the “October Bond TMSA” and, together with the March Bond TMSA, the “Trademark Security Agreements”);

WHEREAS, pursuant to the terms and conditions of the Trademark Security Agreements, the Assignee granted to the Assignor, for the benefit of the Secured Parties, a security interest in and continuing lien on all of the Assignee’s right, title and interest in, to and under the following, in each case whether then owned or thereafter acquired by the Assignee or in which the Assignee then had or thereafter acquired any right, title or interest and wherever the same may be located (collectively, the “Trademark Collateral”):

all United States and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed in Schedule A attached to the Trademark Security Agreements, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of

suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world;

WHEREAS, the March Bond TMSA was recorded with the United States Patent and Trademark Office on July 19, 2017 at Reel 6109, Frame 0623 and the October Bond TMSA was recorded with the United States Patent and Trademark Office on February 26, 2018 at Reel 6280, Frame 0211;

WHEREAS, pursuant to that certain Officers' Certificate dated as of the date hereof (the "Certificate"), Parent certified to the Assignor that the Parent sold the trademarks set forth on Schedule I hereto (the "Specified Trademarks"), which sale has been consummated by the Assignee and the purchaser as of the date hereof, as provided in the Certificate; and

WHEREAS, the Assignor, solely in reliance on the representations, warranties and certifications made pursuant to the Certificate and without independent investigation, has agreed to terminate and release its security interest solely in the Specified Trademarks and Specified Trademark Collateral (as defined below) related thereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor, on behalf of itself, its successors, legal representatives and assigns hereby unconditionally terminates, releases, discharges and reassigns to the Assignee fully, without representation, warranty or recourse, its security interest in and continuing lien on all of the Assignee's right, title and interest in, to and under (i) the Specified Trademarks, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto (but excluding, for the avoidance of doubt, Proceeds from the sale by the Assignee of the Specified Trademarks as referenced in the Certificate), and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Specified Trademark Collateral").

The Assignor hereby authorizes the Assignee or the Assignee's authorized representative to record this Release with the United States Patent and Trademark Office ("USPTO") and any other offices as may be necessary to carry out the intention of this Release, and to the extent applicable, the Assignor authorizes and requests that the USPTO record this Release.

The Assignor shall execute and deliver any and all documents or other instruments reasonably requested by the Assignee, and at the Assignee's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

Delivery of an executed signature page to this Release by facsimile or electronic transmission (including .pdf file) shall be effective as delivery of an original signature.

For the avoidance of any doubt, this Release is strictly limited solely and only to the Specified Trademark Collateral and to no other Trademark Collateral. The Assignor continues to

maintain, without interruption or impairment, its security interest in all of the Assignee's right, title and interest in, to and under all Trademark Collateral other than the Specified Trademark Collateral. The provisions of the Trademark Security Agreements and the Security Agreements shall, except as modified by this Release, continue in full force and effect.

**THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND
ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK
WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.**

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Assignor has caused this Release to be executed and delivered by its duly authorized officer as of the date first set forth above.

THE BANK OF NEW YORK MELLON,
as Collateral Agent

By: 

Name:

Title:

Joellen F. McNamara
Vice President

Signature Page to Release of Security Interest in Specified Trademarks

TRADEMARK
REEL: 006548 FRAME: 0380

SCHEDULE I
to
RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS

Specified Trademarks

Mark Name	Country	Current Owner	Status	Application Date	Serial Number	Registered	Registration No.
TERMINATOR 10	United States	VALEANT PHARMACEUTICALS INTERNATIONAL, Inc.	Registered	May 30, 2007	77193615	July 8, 2008	3460627